- Home
- STSS vs TOVX Comparison
STSS vs TOVX Comparison
Compare STSS & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STSS
- TOVX
- Stock Information
- Founded
- STSS 2017
- TOVX 2001
- Country
- STSS United States
- TOVX United States
- Employees
- STSS N/A
- TOVX N/A
- Industry
- STSS Medical/Dental Instruments
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- STSS Health Care
- TOVX Health Care
- Exchange
- STSS Nasdaq
- TOVX Nasdaq
- Market Cap
- STSS 4.6M
- TOVX 3.8M
- IPO Year
- STSS 2022
- TOVX 2006
- Fundamental
- Price
- STSS $5.87
- TOVX $0.47
- Analyst Decision
- STSS
- TOVX Hold
- Analyst Count
- STSS 0
- TOVX 1
- Target Price
- STSS N/A
- TOVX N/A
- AVG Volume (30 Days)
- STSS 2.6M
- TOVX 1.8M
- Earning Date
- STSS 05-15-2025
- TOVX 05-14-2025
- Dividend Yield
- STSS N/A
- TOVX N/A
- EPS Growth
- STSS N/A
- TOVX N/A
- EPS
- STSS N/A
- TOVX N/A
- Revenue
- STSS N/A
- TOVX N/A
- Revenue This Year
- STSS N/A
- TOVX N/A
- Revenue Next Year
- STSS N/A
- TOVX N/A
- P/E Ratio
- STSS N/A
- TOVX N/A
- Revenue Growth
- STSS N/A
- TOVX N/A
- 52 Week Low
- STSS $3.36
- TOVX $0.40
- 52 Week High
- STSS $2,904.00
- TOVX $7.37
- Technical
- Relative Strength Index (RSI)
- STSS 42.25
- TOVX 29.91
- Support Level
- STSS $3.44
- TOVX $0.43
- Resistance Level
- STSS $7.04
- TOVX $0.54
- Average True Range (ATR)
- STSS 0.51
- TOVX 0.05
- MACD
- STSS 1.33
- TOVX 0.03
- Stochastic Oscillator
- STSS 67.47
- TOVX 41.18
About STSS Sharps Technology Inc.
Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes designed to eliminate potentially infectious and accidental needlestick injuries.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.